Liquid biopsies are a relatively new technique offering a revolutionary approach to cancer detection and monitoring. The minimally invasive method analyses biomarkers within bodily fluids such as blood and serum without the requirement for traditional tissue biopsies, reducing patient recovery time and streamlining the process with the latest technology. Liquid biopsies can allow scientists to identify cancer at an early stage, track tumour progression, assess treatment effectiveness and even enable personalised treatment plans.

In this hour-long webinar – originally broadcast on 4 December – you will hear from two world-leading experts shaping the future of liquid biopsy science. Catherine Alix-Panabières is a globally renowned leader in the field of liquid biopsies. Starting us off, she covers the concept of liquid biopsy as it stands in 2024 – including its history and how the technique has evolved – as well as focussing on the clinical relevance and application of circulating tumour cells. We then hear from Matthew Baker, who is the co-founder and CEO of a company revolutionising liquid biopsy techniques by using AI to enable earlier detection of brain tumours.

This informative and insightful webinar is useful for both industry experts and those working in related fields. Learn how scientists are paving the way for liquid biopsies to become a standard tool shaping the future of cancer care, promising to improve cancer diagnosis, treatment and patient outcomes. 

Speakers

Portrait headshot of Catherine Alix-Panabières

Catherine Alix-Panabières

Catherine is professor of oncology and director of the Laboratory of Rare Circulating Human Cells-Liquid Biopsy at Montpellier University Hospital/Faculty of Medicine. A specialist in circulating tumour cell (CTC) research for 25 years, she is credited with coining the term ‘liquid biopsy’ in 2010. Her most significant contribution is the demonstration of the clinical utility of CTCs in breast cancer. She has been the recipient of numerous awards in France and abroad including a lifetime achievement award from the International Liquid Biopsy Society. Furthermore, Nature, in 2020, acknowledged the significance of liquid biopsy as a pivotal advancement in cancer research over the past two decades and showcased Catherine’s contributions throughout her career.

Portrait headshot of Matt Baker

Matthew Baker

Matt is the inventor of Dxcover’s liquid biopsy platform. Since the company’s inception in 2019, Matt has been responsible for the company’s technical research and development, intellectual property portfolio, and clinical studies strategy and execution. Now as Dxcover CEO, he is leading the company’s mission to be a world leader in liquid biopsy and artificial intelligence for the early detection of cancer while democratising cancer care. He is also professor of early diagnostics in the School of Medicine & Dentistry at the University of Central Lancashire.

Topics